Skip to main content
S&P 5007,636.54+1.54%DOW52,473.68+0.46%NASDAQ25,587.63+2.08%BTC$74,383.00+1.42%ETH$2,080.21+1.87%GOLD$3,996.00-0.85%OIL$87.28+1.44%
Smart Investors Daily
SID Premium
HO

NASDAQ · HOWL

Werewolf Therapeutics, Inc.

Healthcare · Biotechnology

$0.97

Up+$0.01 (+1.03%)

Updated Nov 11, 2026, 7:01 PM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
53.38M
P/E ratio
-0.69
Dividend yield
0.00%
52-week range
$0.27 – $1.21
Volume
217.81K
Avg. volume
938.4K

Price performance · HOWL

HOWL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 10, 2026

HOWL closed at $0.97 after 21 trading sessions, down 2.13% for the selected period.

Last close
$0.97
Period change
-2.13%
Period low
$0.97
Period high
$1.10
Daily close
View OHLC price history
HOWL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 10, 2026$1.01$1.01$0.97$0.97217.81K
Nov 9, 2026$1.03$1.07$1.00$1.01335.19K
Nov 6, 2026$1.02$1.03$0.9826$1.01176.64K
Nov 5, 2026$1.06$1.07$1.00$1.02302.81K
Nov 4, 2026$1.08$1.10$1.05$1.09302.73K
Nov 3, 2026$1.04$1.08$1.03$1.07251.51K
Nov 2, 2026$0.9862$1.06$0.9862$1.05272.2K
Oct 30, 2026$1.09$1.09$0.97$0.9861415.56K
Oct 29, 2026$1.08$1.10$1.0501$1.10400.92K
Oct 28, 2026$1.03$1.08$1.02$1.06388.96K
Oct 27, 2026$0.99$1.05$0.96$1.04308.1K
Oct 26, 2026$0.99$0.9999$0.95$0.9806477.48K
Oct 23, 2026$1.01$1.03$0.9801$0.9801211.04K
Oct 22, 2026$1.01$1.05$1.00$1.01184.16K
Oct 21, 2026$1.05$1.06$1.01$1.03199.37K
Oct 20, 2026$1.03$1.09$1.03$1.05485.74K
Oct 19, 2026$0.9792$1.055$0.9792$1.04378.85K
Oct 16, 2026$1.01$1.01$0.9703$0.98309.25K
Oct 15, 2026$0.9615$1.0176$0.9615$0.997426.22K
Oct 14, 2026$0.99$1.025$0.9657$0.98664.07K
Oct 13, 2026$1.00$1.0101$0.97$0.9911355.21K

Latest HOWL news

The latest Smart Investors Daily articles mentioning HOWL.

Stock researchCompany · Overview

HOWL research

Overview

Company profile and research snapshot.

Company profile

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$12.00
Implied upside
—
Analysts
12
HOWL recent ratings
DateFirmRatingTarget
Dec 19, 2025HC Wainwright & Co.Buy—
Nov 18, 2025B of A SecuritiesBuy—
Aug 25, 2025B of A SecuritiesBuy—
Aug 21, 2025JMP SecuritiesMarket Outperform—
May 9, 2025WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it has been selected for an oral presentation and will present two posters at the upcoming Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting, taking place

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By